Abstract:e21555 Background: Treatment paradigms in advanced melanoma are evolving with the success of new targeted and immunotherapies. The purpose of this study is to explore the outcomes associated with neoadjuvant therapy for advanced melanoma at our institution. Methods: We performed a retrospective analysis of all patients diagnosed with melanoma who received neoadjuvant immunotherapy for locally and regionally advanced primary or recurrent disease at an NCI-designated Comprehensive Cancer Center. Demographic information, primary tumor staging and characteristics, treatment regimen, clinical and pathological responses, and radiologic reports were collected. Results: The analytic cohort consisted of 14 patients who either completed or are receiving neoadjuvant immunotherapy. 11 have a cutaneous primary and 3 have an unknown primary. Treatment regimens consisted of PD-1 inhibitor (n = 9), TVEC (n = 1), combination of PD-1 inhibitor and TVEC (n = 3) and combination of CCR2 and PD-1 inhibitors (n = 1). Prior therapy included Ipilimumab in 3 patients and radiation in 2 patients. 5 patients received neoadjuvant therapy for primary disease and 9 patients received neoadjuvant therapy for recurrent disease. 7 patients had overall clinical response (5 complete response (CR), 2 partial response (PR)), 3 patients had stable disease (SD) and 3 patients had progression. 8 patients underwent surgical resection after therapy, 4 of these patients had clinically SD, 1 patient had a PR and 3 patients had progression. Surgeries performed included excision of 2 primary and 2 recurrent sites, 5 lymph node dissections and 1 resection of in-transit disease. Median time to surgery from the start of immunotherapy was 7.5 months (range 0 - 14). 5 patients had a partial and 3 patients had a complete pathological response. 2 patients continued therapy after resection. An additional 6 patients are currently receiving immunotherapy with intent to undergo resection. Median follow-up time from diagnosis was 27 months (range 10 - 95). Conclusions: At our tertiary referral center select patients with locally and regionally advanced melanoma are considered for neoadjuvant immunotherapy with an overall response in 50% of patients. Further studies are currently pending which will likely validate our results.

Adjuvant immunotherapy for melanoma patients: progress and opportunities

Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing

The Current State of Neoadjuvant Therapy in Resectable Advanced Stage Melanoma

Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma

Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field

Neoadjuvant Therapy in Advanced Melanoma.

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

Advances in treatment of melanoma with immunotherapy

Advances in Adjuvant and Neoadjuvant Therapy for Melanoma

Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View

Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma

Adjuvant Therapy for High-Risk Stage II Melanoma: Current Paradigms in Management and Future Directions

Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials

Neoadjuvant therapy for melanoma: past, present, and future

Into the Future: Fighting Melanoma with Immunity

Adjuvant PD-1 Checkpoint Inhibition in Early Cutaneous Melanoma: Immunological Mode of Action and the Role of Ultraviolet Radiation

Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update

Immunotherapy of Human Melanoma: Past, Present, Future

Adjuvant Immunotherapy in Stage II Melanoma—Further Risk Stratification is Needed

Immunotherapy of Melanoma: a Critical Review of Current Concepts and Future Strategies